TREATMENTOFRENAL ALLOGRAFTCHRONIC REJECTION

V.V. Shelest; R.O. Zograbian

doi:10.31450/ukrjnd.1(57).2018.06

V.V. Shelest National Institute of Surgery and Transplantology named after A.A. Shalimov
R.O. Zograbian National Institute of Surgery and Transplantology named after A.A. Shalimov

DOI: https://doi.org/10.31450/ukrjnd.1(57).2018.06

Keywords: renal allograft chronic rejection, treatment

Abstract

The work is a literature review, which demonstrates the current strategies of the treatment of chronic renal allograft rejection

Downloads

Download data is not yet available.

References

Sellares J, de Freitas D.G., Mengel M, et al. Understandingthe causes of kidney transplant failure: the dominant role of antibody–mediated rejection and nonadherence // Am. J. Transplant. – 2012. – Vol. 12. – p. 88–99.

Mauiyyedi S, Pelle P.D., Saidman S, et al. Chronic humoral rejection: identification of antibody– mediatedchronic renal allograft rejection by C4d deposits in peritubular capillaries // J. Am. Soc. Nephrol. – 2001. – Vol. 12. – p. 74–82.

Regele H., Bohmig G.A., Habicht A., et al. Capillary deposition of complement split product C4din renal allografts is associated with basement membrane injury in peritubularand glomerular capillaries: a contribution of humoral immunityto chronic allograft rejection // J. Am. Soc. Nephrol. – 2002. – Vol. 13. – p. 71–80.

Nankivell B.J., Borrows R.J., Fung C.L., et al. The natural history of chronic allograft nephropathy // N. Engl. J. Med. – 2003. – Vol. 349. – p. 26–33.

Vongwiwatana A., Gourishankar S, Campbell P.M., et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy // Am. J. Transplant. – 2004. – Vol. 4. – p. 4–9.

Ishii Y, Sawada T, Kubota K., et al. Injuryand progressive loss of peritubular capillaries in the development of chronic allograft nephropathy // Kidney Int. – 2005. – Vol. 67. – p. 21–32.

Solez K, Colvin R.B., Racusen L.C., et al. Banff05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy (‘CAN’) // Am. J. Transplant. – 2007. – Vol. 7. – p. 18–26.

Aita K., Yamaguchi Y, Shimizu T, et al. Histological analysis of late renal allografts of antidonor antibody positive patients with C4d deposits in peritubular capillaries // Clin. Transplant. – 2004. – Vol. 18. – p. 7–12.

Cosio F.G., Gloor J.M., Sethi S, et al. Transplant glomerulopathy // Am. J. Transplant. – 2008. – Vol. 8. – p. 2–6.

Pascual J., Perez–Saez M.J., Mir M, et al. Chronic renal allograft injury: early detection, accurate diagnosis and management // Transplant. Rev. – 2012. – Vol. – 26. – p. 80–90.

Einecke G, Sis B, Reeve J., et al. Antibody–mediated microcirculation injury is the major cause of late kidney transplant failure // Am. J. Transplant. – 2009. – Vol. 9. – p. 20–31.

Stegall M.D., Chedid M.F., Cornell L.D. The role of complement in antibody mediated rejection in kidney transplantation // Nat. Rev. Nephrol. – 2012. – Vol. 8. – p. 6–8.

Lee P.C., Terasaki P.I., Takemoto S.K., et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies // Transplantation. – 2002. – Vol. 74. – p. 2–4.

Everly M.J., Rebellato L.M., Haisch C.E., et al. Incidence and impact of de novo donor–specific alloantibody in primary renal allografts // Transplantation. – 2013. – Vol. 95. – p. 4–7.

Wiebe C, Gibson I.W., Blydt–Hansen T.D., et al. Evolution and clinical pathologic correlations of de novo donor–specific HLA antibody post kidney transplant // Am. J. Transplant. – 2012. – Vol. 12. – p. 57–67.

Husain S., Sis B. Advances in the understanding of transplant glomerulopathy // Am. J. Kidney. Dis. – 2013. – Vol. 62. – p. 52–63.

Solez K, Colvin R.B., Racusen L.C., et al. Banff 07 classification of renal allograft pathology: updates and future directions // Am. J. Transplant. – 2008. –Vol. 8. – p. 53–60.

Gloor J.M., Cosio F.G., Rea D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation // Am. J. Transplant. – 2006. – Vol. 6. – p. 1–7.

Ishida H, Furusawa M, Shimizu T, et al. Influence of preoperative anti–HLA antibodies on short– and long–term graft survival in recipients with or without rituximab treatment // Transpl. Int. – 2014. – Vol. 27. – p. 71–82.

Hirai T, Kohei N, Omoto K., et al. Significance of low–level DSA detected by solid–phase assay in association with acute and chronic antibody–mediated rejection // Transpl. Int. – 2012. – Vol. 25. – p. 25–34.

Pascual J, Perez–Saez M.J., Mir M, et al. Chronic renal allograft injury: early detection, accurate diagnosis and management // Transplant. Rev. (Orlando). – 2012. – Vol. 26. – p. 80–90.

Colvin R.B. Antibody–mediated renal allograft rejection: diagnosis and pathogenesis // J. Am. Soc. Nephrol. – 2007. – Vol. 18. – p. 46–56.

Hong Y.A., Kim H.G., Choi S.R., et al. Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody–mediated rejection // Transplant. Proc. – 2012. – Vol. 44. – p. 2–4.

Terasaki P.I., Ozawa M. Predictive value of HLA antibodies and serum creatinine in chronic rejection: results of a 2–year prospective trial // Transplantation. – 2005. – Vol. 80. – p. 4–7.

Vo A.A., Lukovsky M, Toyoda M, et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation // N. Engl. J. Med. – 2008. – Vol. 359. – p. 42–51.

Salama A.D., Pusey C.D. Drug insight: rituximab in renal disease and transplantation // Nat. Clin. Pract. Nephrol. – 2006. – Vol. 2. – p. 21–30.

Billing H, Rieger S, Ovens J., et al. Successful treatment of chronic antibody–mediated rejection with IVIG and rituximab in pediatric renal transplant recipients // Transplantation. – 2008. – Vol. 86. – p. 14–21.

Kohei N., Hirai T., Omoto K., et al. Chronic antibody–mediated rejection is reduced by targeting B–cell immunity during an introductory period // Am. J. Transplant. – 2012. – Vol. 12. – p. 69–76.

Smith R.N., Malik F., Goes N., et al. Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts // Transpl. Immunol. – 2012. – Vol. 27. – p. 7–13.

Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin // N. Engl. J. Med. – 2001. – Vol. 345. – p. 47–55.

Jordan S.C., Vo A.A., Peng A., et al. Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA–sensitized patients // Am. J. Transplant. – 2006. – Vol. 6. – p. 59–66.

Jordan S.C., Quartel A.W., Czer L.S., et al. Posttransplant therapy using high–dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action // Transplantation. – 1998. – Vol. 66. – p. 5.

Jordan S.C., Vo A., Bunnapradist S, et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living–donor and cadaver recipients // Transplantation. – 2003. – Vol. 76. – p. 1–6.

Billing H., Rieger S., Susal C, et al. IVIG and ritux–imab for treatment of chronic antibody–mediated rejection: a prospective study in paediatric renal transplantation with a 2–year follow–up // Transpl. Int. – 2012. – Vol. 25. – p. 65–73.

Fehr T., Rusi B., Fischer A., et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody–mediated kidney allograft rejection // Transplantation. – 2009. – Vol. 87. – p. 37–41.

An G.H., Yun J., Hong Y.A., et al. The effect of combination therapy with Rituximab and Intravenous immunoglobulin on the progression of chronic antibody mediated rejection in renal transplant recipients // J. Immunol. Res. – 2014. – Vol. 20. – p. 32.

Clatworthy M.R. Targeting B cells and antibody in transplantation // Am. J. Transplant. – 2011. – Vol. 11. – p. 59–67.

Everly M.J. A summary of bortezomib use in transplantation across 29 centers // Clin. Transplant. – 2009. – Vol. 3. – p. 23–37.

Schwaiger E, Regele H, Wahrmann M, et al. Bortezomib for the treatment of chronic antibody– mediated kidney allograft rejection: a case report // Clin. Transplant. – 2010. –Vol. 3. – p. 1–6.

Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production // Am. J. Transplant. – 2009. – Vol. 9. – p. 1–9.

Everly M.J. An update on antibody reduction and rejection reversal following bortezomib use: a report of 52 cases across 10 centers // Clin. Transplant. – 2010. – Vol. 3. – p. 53–62.

Yang K.S., Jeon H, Park Y, et al. Use of bort– ezomib as anti–humoral therapy in kidney transplantation // J. Korean Med. Sci. – 2014. – Vol. 29. – p. 48–51.

Vogelbacher R., Meister S, Guckel E, et al. Bortezomib and sirolimus inhibit the chronic active antibody–mediated rejection in experimental renal transplantation in the rat // Nephrol. Dial. Transplant. – 2010. – Vol. 25. – p. 64–73.

Kim M.G., Kim Y.J., Kwon H.Y., et al. Outcomes of combination therapy for chronic antibody–mediated rejection in renal transplantation // Nephrology (Carlton). – 2013. – Vol. 18. – p. 6.

Larrea C.F., Cofan F., Oppenheimer F., et al. Efficacy of eculizumab in the treatment of recurrent atypical hemolytic–uremic syndrome after renal transplantation // Transplantation. – 2010. – Vol. 89. – p. 3–4.

Bi B, Schmitt R., Israilova M, et al. Stromal cells protect against acute tubular injury via an endocrine effect // J. Am. Soc. Nephrol. – 2007. – Vol. 18. – p. 86–96.

Picinich S.C., Mishra P.J., Glod J., et al. The therapeutic potential of mesenchymal stem cells. Cell– & tissue–based therapy // Expert. Opin. Biol. Ther. – 2007. – Vol. 7. – p. 65–73.

Hematti P. Role of mesenchymal stromal cells in solid organ transplantation // Transplant. Rev. (Orlando). – 2008. – Vol. 22. – p. 62–73.

Togel F, Weiss K, YangY., et al. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury // Am. J. Physiol. Renal. Physiol. – 2007. – Vol. 292. – p. 26–35.